Discussion of the process control of large-scale instruments and equipment procurement in State Key Laboratory

doi:10.5246/jcps.2020.03.019

Abstract

Abstract:

In recent years, the usage, management and benefit of large-scale scientific research instruments and equipment in scientific research institutes have been a leading issue in the management of scientific research institutes. Within the scope of equipment budget, it is necessary for each equipment acquisition team to conduct a round of communication, coordination and negotiation with suppliers in order to improve the cost performance of equipment procurement and maximize the performance index to meet the needs of scientific research. By introducing the practical experience of the State Key Laboratory in purchasing imported equipment and managing large-scale instruments, this paper probes into the management process of the imported large-scalescientific research tax-free equipment of scientific research institutes, and explores the system and methods to guarantee and improve the efficiency of large-scale instruments in scientific research institutes from the aspects of policy, funds and technology.

Key words: Large-scale scientific research instruments procurement, Bidding and tender, Process control

CLC Number:

Supporting:

Shuxiang Song. Discussion of the process control of large-scale instruments and equipment procurement in State Key Laboratory[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(3): 214-219.

[1]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[2]	Chengxin Xie, Wei Wang, Ge Huang, Xin Jin, Chenglong Wang, Dong Yin. Pharmacist-led interventions to reduce inappropriate drug use in the orthopaedics department in China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 375-382.
[3]	Yuyao Nie, He Wang, Linguang Zhou, Luwen Shi, Bin Jiang. Pharmacists’ perceptions of generic drugs in China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 364-368.
[4]	Zhifeng Nie, Chunxia Man, Xin Yi, Yi Liu, Zhigang Guo, Xiaodong Guan, Luwen Shi. Impact of the zero-markup drug policy on volume of medical service: based on 57 county hospitals of China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(3): 220-226.
[5]	Ruojing Zhou, Bin Jiang. Effects of drug purchasing under joint price caps policy in Fujian Province, China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(2): 139-152.
[6]	Shuxiang Song. Retrospect and reflection on the construction of large-scale technology platform of the State Key Laboratory of Natural and Biomimetic Drugs in 2018-2020 [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(12): 878-884.
[7]	Ruirui Zhou, Liqun Wang, Tong Sun, Ziyang Wu, Xiaohui Xie. The efficacy and safety of three types of combination therapies in patients with moderate to very severe COPD: a systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 502-518.
[8]	Zhuangfei Wang, Xiaodong Guan, Yue Zhou, Sheng Han, Peng Yao, Luwen Shi. Prevalence and influence factors of self-medication in Chinese middle-aged and elderly people: evidence from 2011, 2013 and 2015 CHARLS panel data [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 430-438.
[9]	Dongsheng Yang, Lingyun Ma, Jianzhao Niu, Mingdi Xu. Brief introduction for application of USA authorized generic drugs [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 439-445.
[10]	Zhiyong Dong, Xiantu Qiu, Stacy A. Kujawa, S.M. Shariful Islam, Jie Zhang. Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 264-275.
[11]	Min Chen, Feng Jiang, Ming Zheng, Limei Yang, Hongjin Gao. Design and implementation of mobile APP for medication guidance related to pharmacogenomic based on APICloud platform [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 276-283.
[12]	Qi Zhang, Bo Zhang, Nengming Lin. Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 195-202.
[13]	Dongsheng Yang, Lingyun Ma, Jianzhao Niu, Mingdi Xu. Brief introduction for application of the USA national drug code [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 203-208.
[14]	Xinpu Lu, Zhigang Guo, Mengyuan Fu, Haishaerjiang Wushouer, Luwen Shi, Xiaodong Guan. The impacts of national essential medicine policies on the rational use of medicines in China: A cross-sectional study in primary health care institution [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 49-55.
[15]	Chao Zhang, Ruohan Xie, Chuhui Wang, Chenchen Xi, Mengjia Ge. Dose optimization of piperacillin/tazobactam in patients with renal dysfunction based on population pharmacokinetic and pharmacodynamic simulations [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(12): 824-831.

Discussion of the process control of large-scale instruments and equipment procurement in State Key Laboratory

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments